Use of fidaxomicin through a nasogastric tube for the treatment of septic shock caused by Clostridium difficile infection in a patient with oral cancer admitted to the Surgical Critical Care Unit

Revista Espanola de Quimioterapia

Volumn 26, Issue 4, 2013, Pages 375-377

  Maseda, Emilio ^a   Hernandez Gancedo, Carmen ^a   Lopez Tofiño, Araceli ^a   Suarez de la Rica, Alejandro ^a   Garcia Bujalance, Silvia ^a   Gilsanz, Fernando ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; FIDAXOMICIN;

AGED; CARCINOMA, SQUAMOUS CELL; CASE REPORT; COMPLICATION; CROSS INFECTION; DIGESTIVE TRACT INTUBATION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HUMAN; INTENSIVE CARE; MANDIBULAR NEOPLASMS; MICROBIOLOGY; MOUTH TUMOR; NECROSIS; PEPTOCLOSTRIDIUM DIFFICILE; PROCEDURES; SHOCK, SEPTIC;

AGED; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CARCINOMA, SQUAMOUS CELL; CLOSTRIDIUM DIFFICILE; CRITICAL CARE; CROSS INFECTION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HUMANS; INTENSIVE CARE; INTUBATION, GASTROINTESTINAL; MANDIBULAR NEOPLASMS; MOUTH NEOPLASMS; NECROSIS; SHOCK, SEPTIC;

EID: 84894346596     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (23)

1. Voth DE, Ballard JD. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 2005; 18: 247-63.
2. Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik M, et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011; 377: 63-73.
3. Bobo LD, Dubberke ER. Recognition and prevention of hospital-associated enteric infections in the intensive care unit. Crit Care Med 2010; 38(8 Suppl): S324-34.
4. Riddle DJ, Dubberke ER. Clostridium difficile infection in the intensive care unit. Infect Dis Clin North Am 2009; 23: 727-43.
5. Zahar JR, Schwebel C, Adrie C, Garrouste-Orgeas M, Français A, Vesin A, et al. Outcome of ICU patients with Clostridium difficile infection. Crit Care 2012; 16: R215.
6. Bobo LD, Dubberke ER, Kollef M. Clostridium difficile in the ICU: the struggle continues. Chest 2011; 140: 1643-53.
7. Binion DG. Clostridium difficile infection in patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y) 2012; 8: 615-7.
8. Pepin J, Alary ME, Valiquette L, Raiche E, Ruel J, Fulop K, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40: 1591-7.
9. Stevens V, Dumyati G, Fine LS, Fisher SG, van Wijngaarden E. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis 2011; 53: 42-8.
10. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31: 431-55.
11. Debast SB, Bauer MP, Kuijper EJ; The Committee. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): update of the treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2013 Oct 5. doi: 10. 1111/1469-0691. 12418. [Epub ahead of print].
12. Cornely OA, Miller MA, Fantin B, Mullane K, Kean Y, Gorbach S. Clinical outcomes for cancer patients with Clostridium difficile infection. Abstracts of 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), London 2012, abstract 2289.
13. Mullane KM, Cornely OA, Crook DW, Golan Y, Louie TJ, Miller MA, et al. Renal impairment and response to fidaxomicin versus vancomycin in patients with Clostridium difficile infection. Abstracts of the 49th Annual Meeting of the Infectious Diseases Society of America and the HIV Medicine Association, Boston 2011, abstract 759.
14. Cornely OA. Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?. Clin Microbiol Infect 2012; 18 (Suppl 6): 28-35.
15. Dodek PM, Norena M, Ayas NT, Romney M, Wong H. Length of stay and mortality due to Clostridium difficile infection acquired in the intensive care unit. J Crit Care 2013; 28: 335-40.
16. Kenneally C, Rosini JM, Skrupky LP, Doherty JA, Hollands JM, Martinez E, et al. Analysis of 30-day mortality for Clostridium difficile-associated disease in the ICU setting. Chest 2007; 132: 418-24.
17. Zilberberg MD, Shorr AF, Micek ST, Doherty JA, Kollef MH. Clostridium difficile-associated disease and mortality among the elderly critically ill. Crit Care Med 2009; 37: 2583-9.
18. Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis 2008; 14: 929-31.
19. Pépin J, Valiquette L, Alary ME, Villemure P, Pelletier A, Forget K, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004; 171: 466-72.
20. Louie TJ, Miller MA, Crook DW, Lentnek A, Bernard L, High KP, et al. Effect of age on treatment outcomes in Clostridium difficile infection. J Am Geriatr Soc 2013; 61: 222-30.
21. Simor AE. Diagnosis, management, and prevention of Clostridium difficile infection in long-term care facilities: a review. J Am Geriatr Soc 2010; 58: 1556-64.
22. Smeltzer S, Hassoun A. Successful use of fidaxomicin in recurrent Clostridium difficile infection in a child. J Antimicrob Chemother 2013; 68: 1688-9.
23. Redell M, Tousseeva A, Hui M, et al. Stability of fidaxomicin crushed tablet in three delivery vehicles (Water, Applesauce, and Ensure) and administration of a water preparation via nasogastric tube. Abstracts of the Annual Meeting of the American Society of Clinical Pathologists 2012, Boston, poster 34.